You have read all your free articles, to continue reading subscribe to read the rest of this content.
Medivir and Ascletis announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir's nucleotide polymerase inhibitor for hepatitis C, MIV-802 (Ascletis code: ASC21), in Greater China. Under the terms of the agreement, Medivir received an upfront paymeAlready a subscriber Login You have read all your free articles,…
Novo Nordisk has announced plans to invest more than 17 billion Danish kroner in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark. The investment will establish additional capacity across the entire gAlready a subscriber Login You have…
At the end of August, LEO Pharma announced that it will accelerate its R&D efforts and diversify its portfolio of medicines to cover a range of dermatological indications including rare diseases. The company is aiming to launch a new innovative treatment every 2-3 years, it states. “BuilAlready a subscriber Login…
Oasmia Pharmaceutical has signed an agreement with Kazia Therapeutics, an Australian oncology-focused biotechnology company, to acquire exclusive global development rights for Cantrixil, a product candidate in development intended for the treatment of ovarian cancer. The agreement is the first inAlready a subscriber Login You have read all your free articles,…
